Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
How Does Repatha Work for High Cholesterol? People can have high cholesterol for a number of reasons, including their diet, exercise habits, or genetic conditions. Keeping your cholesterol low, ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...
THOUSAND OAKS, Calif., May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab) ...
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...
Hosted on MSN
Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention
Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...
Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
Amgen has announced that the price of its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab (Repatha), will be reduced by 60%, from an annual price of $14,100 down to $5850.
The U.S. Supreme Court is breaking out the big guns to help make sense of Amgen and Sanofi's long-running PCSK9 patent feud. “The Solicitor General is invited to file a brief in this case expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback